Pacific Biosciences of California, Inc. (BMV:PACB)

BMV:PACB Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-50.05	-61.62	-62.49	-77.7	-78.21
Depreciation & Amortization	3.42	3.25	3	2.52	3
Stock-Based Compensation	4.38	5.39	10.63	22.05	16.46
Other Adjustments	15.46	7.85	-1.61	6.52	12.06
Change in Receivables	0.44	-0.23	-0.1	-0.89	1.59
Changes in Inventories	-0.05	0.45	-0.24	-0.42	-1.36
Changes in Accounts Payable	0.79	0.3	2.92	0.27	-1.01
Changes in Accrued Expenses	-0.95	1.38	-0.64	-0.75	-0.91
Changes in Unearned Revenue	1.25	2.12	0.1	0.08	0.11
Changes in Other Operating Activities	1.1	0.93	-0.29	1	-2.13
Operating Cash Flow	-24.19	-40.2	-48.73	-47.32	-50.39
Capital Expenditures	-0.51	-1.04	-0.55	-0.6	-1.36
Purchases of Investments	-	-	-27.51	-30.08	-46.93
Proceeds from Sale of Investments	-	9.7	40.48	38.99	61.9
Investing Cash Flow	-0.51	8.66	12.42	8.3	13.61
Long-Term Debt Issued	15	10	-	-	5.58
Long-Term Debt Repaid	-0.73	-	-0.08	-0.36	-0.37
Net Long-Term Debt Issued (Repaid)	14.27	10	-0.08	-0.36	5.21
Issuance of Common Stock	15.5	4	33.1	44.83	6.42
Net Common Stock Issued (Repurchased)	15.5	4	33.1	44.83	6.42
Other Financing Activities	-2.73	-4.98	-1.39	-1.24	-
Financing Cash Flow	27.05	9.02	31.63	43.23	11.63
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.61	-0.25	-0.31	-0.09	-0.08
Net Cash Flow	2.96	-22.77	-4.99	4.12	-25.23
Beginning Cash & Cash Equivalents	12.14	34.91	39.9	35.78	61.01
Ending Cash & Cash Equivalents	15.1	12.14	34.91	39.9	35.78
Free Cash Flow	-24.7	-41.23	-49.28	-47.93	-51.76
FCF Margin	-211.17%	-341.91%	-386.46%	-406.77%	-463.56%
Levered Free Cash Flow	-30.71	-44.23	-58.28	-75.96	-76.66
Unlevered Free Cash Flow	-30.2	-47.4	-58.43	-69.5	-67.36

Updated Dec 31, 2024. Data Source: Fiscal.ai. Standard template. Financial Sources.